Jarad M Martin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4755218/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Should brachytherapy be added to external beam radiotherapy for prostate cancer?. Lancet Oncology, The, 2022, 23, 23-25.	5.1	6
2	Comparison of Synthetic Computed Tomography Generation Methods, Incorporating Male and Female Anatomical Differences, for Magnetic Resonance Imaging-Only Definitive Pelvic Radiotherapy. Frontiers in Oncology, 2022, 12, 822687.	1.3	5
3	Validation of an MRI-only planning workflow for definitive pelvic radiotherapy. Radiation Oncology, 2022, 17, 55.	1.2	7
4	It's All the RAVE: Time to Give up on the "Chronic Radiation Proctitis―Misnomer. Gastroenterology, 2021, 160, 635-638.	0.6	17
5	Visualising the urethra for prostate radiotherapy planning. Journal of Medical Radiation Sciences, 2021, 68, 282-288.	0.8	7
6	Automatic radiotherapy delineation quality assurance on prostate MRI with deep learning in a multicentre clinical trial. Physics in Medicine and Biology, 2021, 66, 195008.	1.6	7
7	Population-Level Uptake of Moderately Hypofractionated Definitive Radiation Therapy in the Treatment of Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 111, 417-423.	0.4	6
8	Optimisation and validation of an integrated magnetic resonance imaging-only radiotherapy planning solution. Physics and Imaging in Radiation Oncology, 2021, 20, 34-39.	1.2	5
9	Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New Zealand. JAMA Network Open, 2021, 4, e2129647.	2.8	13
10	Letter to the Editor in Response to "The "ltis―in Chronic Radiation Proctitis is alrightis but RAVE is too superficial a shave". Gastroenterology, 2021, , .	0.6	0
11	A prospective, multi-centre trial of multi-parametric MRI as a biomarker in anal carcinoma. Radiotherapy and Oncology, 2020, 144, 7-12.	0.3	9
12	Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG) Tj ETQqO 0 0 rgl 2020, 21, 1331-1340.	3T /Overlo 5.1	ck 10 Tf 50 3 197
13	Response to MM Rojas-Rojas et al. Radiotherapy and Oncology, 2020, 147, 239.	0.3	0
14	Is multileaf collimator tracking or gating a better intrafraction motion adaptation strategy? An analysis of the TROG 15.01 stereotactic prostate ablative radiotherapy with KIM (SPARK) trial. Radiotherapy and Oncology, 2020, 151, 234-241.	0.3	10
15	Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet, The, 2020, 395, 1208-1216.	6.3	1,108
16	Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial. International Journal of Radiation Oncology Biology Physics, 2020, 107, 530-538.	0.4	33
17	FDG-PET parameters predict for recurrence in anal cancer – results from a prospective, multicentre clinical trial. Radiation Oncology, 2019, 14, 140.	1.2	22
18	A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer. BJU International, 2019, 124, 31-36.	1.3	27

#	Article	IF	CITATIONS
19	Assessment and predictors of fatigue in men with prostate cancer receiving radiotherapy and androgen deprivation therapy. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 683-690.	0.9	7
20	The accuracy and precision of the KIM motion monitoring system used in the multiâ€institutional TROG 15.01 Stereotactic Prostate Ablative Radiotherapy with KIM (SPARK) trial. Medical Physics, 2019, 46, 4725-4737.	1.6	14
21	Dosimetric impact of intrafraction rotations in stereotactic prostate radiotherapy: A subset analysis of the TROG 15.01 SPARK trial. Radiotherapy and Oncology, 2019, 136, 143-147.	0.3	22
22	Phase 2 Multicenter Study of Gantry-Based Stereotactic Radiotherapy Boost for Intermediate and High Risk Prostate Cancer (PROMETHEUS). Frontiers in Oncology, 2019, 9, 217.	1.3	30
23	Reduced motion and improved rectal dosimetry through endorectal immobilization for prostate stereotactic body radiotherapy. British Journal of Radiology, 2019, 92, 20190056.	1.0	15
24	Reply to J. David et al. Journal of Clinical Oncology, 2019, 37, 441-441.	0.8	4
25	TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol. BMJ Open, 2019, 9, e030731.	0.8	18
26	A Multi-center Prospective Study for Implementation of an MRI-Only Prostate Treatment Planning Workflow. Frontiers in Oncology, 2019, 9, 826.	1.3	24
27	A clinicianâ€centred programme for behaviour change in the optimal use of staging investigations for newly diagnosed prostate cancer. BJU International, 2018, 121, 22-27.	1.3	14
28	Moderate hypofractionation for prostate cancer: A user's guide. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 232-239.	0.9	11
29	The first clinical implementation of real-time image-guided adaptive radiotherapy using a standard linear accelerator. Radiotherapy and Oncology, 2018, 127, 6-11.	0.3	54
30	Moderately hypofractionated prostate external-beam radiotherapy: an emerging standard. British Journal of Radiology, 2018, 91, 20170807.	1.0	12
31	Oncologist provision of smoking cessation support: A national survey of Australian medical and radiation oncologists. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 431-438.	0.7	15
32	Prostate Cancer Radiotherapy: An Evolving Paradigm. Journal of Clinical Oncology, 2018, 36, 2909-2913.	0.8	9
33	Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method. Radiotherapy and Oncology, 2018, 128, 308-314.	0.3	12
34	PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol. BMC Cancer, 2018, 18, 588.	1.1	16
35	The impact of contour variation on tumour control probability in anal cancer. Radiation Oncology, 2018, 13, 97.	1.2	4
36	Attenuation of Metabolic Syndrome by EPA/DHA Ethyl Esters in Testosterone-Deficient Obese Rats. Marine Drugs, 2018, 16, 182.	2.2	7

#	Article	IF	CITATIONS
37	Spinal multiparametric MRI and DEXA changes over time in men with prostate cancer treated with androgen deprivation therapy: a potential imaging biomarker of treatment toxicity. European Radiology, 2017, 27, 995-1003.	2.3	8
38	Utility of ⁶⁸ Ga prostate specific membrane antigen – positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 372-378.	0.9	83
39	Stereotactic prostate adaptive radiotherapy utilising kilovoltage intrafraction monitoring: the TROG 15.01 SPARK trial. BMC Cancer, 2017, 17, 180.	1.1	39
40	The first clinical implementation of a real-time six degree of freedom target tracking system during radiation therapy based on Kilovoltage Intrafraction Monitoring (KIM). Radiotherapy and Oncology, 2017, 123, 37-42.	0.3	39
41	Regression and statistical shape model based substitute CT generation for MRI alone external beam radiation therapy from standard clinical MRI sequences. Physics in Medicine and Biology, 2017, 62, 8566-8580.	1.6	8
42	Management of early anal cancer: need for guidelines and standardisation. International Journal of Colorectal Disease, 2017, 32, 1719-1724.	1.0	5
43	Technical note: TROG 15.01 SPARK trial multiâ€institutional imaging dose measurement. Journal of Applied Clinical Medical Physics, 2017, 18, 358-363.	0.8	10
44	Patients' Experiences of Preparation for Radiation Therapy: A Qualitative Study. Oncology Nursing Forum, 2017, 44, E1-E9.	0.5	10
45	Rectal protection in prostate stereotactic radiotherapy: a retrospective exploratory analysis of two rectal displacement devices. Journal of Medical Radiation Sciences, 2017, 64, 266-273.	0.8	13
46	Prostate-Specific Membrane Antigen Positron Emission Tomography–Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning. International Journal of Radiation Oncology Biology Physics, 2017, 99, 701-709.	0.4	48
47	Real-time in vivo rectal wall dosimetry using MOSkin detectors during linac based stereotactic radiotherapy with rectal displacement. Radiation Oncology, 2017, 12, 41.	1.2	17
48	Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 1884-1890.	0.8	521
49	Fast automated segmentation of multiple objects via spatially weighted shape learning. Physics in Medicine and Biology, 2016, 61, 8070-8084.	1.6	11
50	A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes. Radiation Oncology, 2015, 10, 243.	1.2	8
51	Investigation on the performance of dedicated radiotherapy positioning devices for MR scanning for prostate planning. Journal of Applied Clinical Medical Physics, 2015, 16, 4-13.	0.8	10
52	Outcomes of nodal metastatic cutaneous squamous cell carcinoma of the head and neck treated in a regional center. Head and Neck, 2015, 37, 1808-1815.	0.9	32
53	The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2015, 22, 3574-3581.	0.7	98
54	MRI simulation: end-to-end testing for prostate radiation therapy using geometric pelvic MRI phantoms. Physics in Medicine and Biology, 2015, 60, 3097-3109.	1.6	34

#	Article	IF	CITATIONS
55	Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks?. Radiation Oncology, 2015, 10, 38.	1.2	36
56	Multiparametric MRI as an outcome predictor for anal canal cancer managed with chemoradiotherapy. BMC Cancer, 2015, 15, 281.	1.1	22
57	Automatic Substitute Computed Tomography Generation and Contouring for Magnetic Resonance Imaging (MRI)-Alone External Beam Radiation Therapy From Standard MRI Sequences. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1144-1153.	0.4	151
58	Optimizing Radiation Therapy Quality Assurance in Clinical Trials: A TROG 08.03 RAVES Substudy. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1045-1051.	0.4	11
59	Incremental changes verses a technological quantum leap: The additional value of intensityâ€modulated radiotherapy beyond imageâ€guided radiotherapy for prostate irradiation. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 503-510.	0.9	6
60	Extracranial oligometastatic renal cell carcinoma: current management and future directions. Future Oncology, 2014, 10, 761-774.	1.1	27
61	<scp>FROGG</scp> highâ€risk prostate cancer workshop: Patterns of practice and literature review. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 257-265.	0.9	4
62	Circulating tumor cell detection in high-risk non-metastatic prostate cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 2157-2162.	1.2	50
63	Rapid determination of vertebral fat fraction over a large range of vertebral bodies. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 155-163.	0.9	18
64	<scp>FROGG</scp> highâ€risk prostate cancer workshop: Patterns of practice and literature review. Part II postâ€radical prostatectomy. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 392-400.	0.9	6
65	Coeliac Patients Are Undiagnosed at Routine Upper Endoscopy. PLoS ONE, 2014, 9, e90552.	1.1	14
66	Patterns of management and surveillance imaging amongst medical oncologists in <scp>A</scp> ustralia for stage <scp>I</scp> testicular cancer. BJU International, 2013, 112, E35-43.	1.3	14
67	Long-term outcome for prostate cancer using pseudo pulse–dosed rate brachytherapy, external beam radiotherapy, and hormones. Brachytherapy, 2013, 12, 608-614.	0.2	3
68	Prostate radiotherapy clinical trial quality assurance: How real should real time review be? (A) Tj ETQq0 0 0 rgB	T /Overlock	10 ₁₂ 50 222
69	Defining a dose–response relationship for prostate external beam radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 237-246.	0.9	16
70	Perineural Infiltration of Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma Without Clinical Features. International Journal of Radiation Oncology Biology Physics, 2012, 82, 334-340.	0.4	77
71	Prostate Contouring Variation: Can It Be Fixed?. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1923-1929.	0.4	64
72	Complementary and Alternative Medicine Use in Radiotherapy: What Are Patients Using?. Journal of Alternative and Complementary Medicine, 2012, 18, 1014-1020.	2.1	34

Jarad M Martin

#	Article	IF	CITATIONS
73	Tubular breast carcinoma: An argument against treatment deâ€escalation. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 116-122.	0.9	9
74	Pharmacotherapeutic Management of Locally Advanced Prostate Cancer. Drugs, 2011, 71, 1019-1041.	4.9	34
75	Dosimetric effect of external beam planning preceding combined high-dose-rate brachytherapy of the prostate. Brachytherapy, 2011, 10, 474-478.	0.2	1
76	Successful Implementation of Image-Guided Radiation Therapy Quality Assurance in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1576-1581.	0.4	25
77	Development of a dosimetry inter-comparison for IMRT as part of site credentialing for a TROG multi-centre clinical trial for prostate cancer. Australasian Physical and Engineering Sciences in Medicine, 2011, 34, 195-202.	1.4	11
78	A comparison of kV and MV imaging in head and neck image guided radiotherapy. Radiography, 2010, 16, 8-13.	1.1	11
79	Is Radiotherapy a Good Adjuvant Strategy for Men With a History of Cryptorchism and Stage I Seminoma?. International Journal of Radiation Oncology Biology Physics, 2010, 76, 65-70.	0.4	3
80	Image and isocentre management in the paperless age: an automated decision making model. Radiographer, 2009, 56, 21-26.	0.1	0
81	Paperless and paper-based processes in the modern radiotherapy department. Radiography, 2009, 15, 300-305.	1.1	9
82	Radiotherapy for perineural invasion in cutaneous head and neck carcinomas: Toward a riskâ€adapted treatment approach. Head and Neck, 2009, 31, 604-610.	0.9	92
83	Reply: Existence of MRIâ€negative clinical (large nerve) perineural squamous cell carcinoma spread. Head and Neck, 2009, 31, 1532-1533.	0.9	Ο
84	Image guided dose escalated prostate radiotherapy: still room to improve. Radiation Oncology, 2009, 4, 50.	1.2	57
85	The impact of IGRT for prostate radiotherapy on dosimetry and the traditional workflow practice of focus to skin distance measurements. Radiographer, 2009, 56, 15-20.	0.1	2
86	Effect of Radiotherapy Volume and Dose on Secondary Cancer Risk in Stage I Testicular Seminoma. International Journal of Radiation Oncology Biology Physics, 2008, 70, 853-858.	0.4	52
87	Intraprostatic fiducials for image guidance: Workflow implications in a single linac department. Radiography, 2008, 14, 312-317.	1.1	8
88	A 3D conformal radiation therapy class solution for dose escalated prostate irradiation. Radiographer, 2008, 55, 13-17.	0.1	3
89	Evidence-based guidelines for following stage 1 seminoma. Cancer, 2007, 109, 2248-2256.	2.0	73
90	Phase II Trial of Hypofractionated Image-Guided Intensity-Modulated Radiotherapy for Localized Prostate Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1084-1089.	0.4	139

#	Article	IF	CITATIONS
91	Treatment Options, Prognostic Factors and Selection of Treatment in Stage I Seminoma. Oncology Research and Treatment, 2006, 29, 592-598.	0.8	9
92	Late Relapses of Germ Cell Malignancies: Incidence, Management, and Prognosis. Journal of Clinical Oncology, 2006, 24, 5503-5511.	0.8	139
93	Low and intermediate risk prostate cancer role of hormonal therapy with external beam radiation therapy. Canadian Journal of Urology, 2006, 13 Suppl 2, 63-7.	0.0	1
94	Towards individualised radiotherapy for Stage I seminoma. Radiotherapy and Oncology, 2005, 76, 251-256.	0.3	23
95	Outcomes in sinonasal mucosal melanoma. ANZ Journal of Surgery, 2004, 74, 838-842.	0.3	28
96	Paranasal sinus tumors: Peter maccallum cancer institute experience. Head and Neck, 2004, 26, 322-330.	0.9	74
97	Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma. Head	0.9	108